Page 18 - 《中国药房》2022年17期

中成药防治重大慢性病的药物经济学评价体系构建 Δ

1
1
3
2
1
1 #
4
徐 敢 ，罗卫花 ，王玉伟 ，郭冬梅 ，叶 桦 ，孙 昱 ，庄 伟 ，朱文涛 （1.北京中医药大学管理学院，北京
1＊
102488；2.复旦大学药学院，上海 201203；3.国家药品监督管理局药品审评中心，北京 100022；4.首都医科大
学宣武医院药剂科，北京 100053）
中图分类号 R956；R288 文献标志码 A 文章编号 1001-0408（2022）17-2060-05
DOI 10.6039/j.issn.1001-0408.2022.17.03
摘 要 目的 探索构建中成药防治重大慢性病的药物经济学评价体系。方法 分析中成药防治重大慢性病药物经济学评价存在
的问题，以问题为导向，探索可用于系统评价中成药防治重大慢性病的药物经济学理论、工具和方法，构建相关药物经济学评价体
系。结果与结论 中医药防治重大慢性病有优势，这种独特优势需要在药物经济学评价中得到挖掘、体现和证明。中成药的药物
经济学评价近年来获得了一定发展，但是中成药防治重大慢性病优势的药物经济学评价仍存在理论和方法学方面的不足，简单套
用化学药的经济学评价指标及技术很难真实、全面地体现中成药的价值。应该围绕中成药药物经济学特有属性，挖掘中成药“治
未病”和发挥人体自身调节作用的经济学价值指标，统筹考虑中成药药物经济学在研究设计、研究角度、目标人群、干预措施和对
照选择、研究时限、评价方法等方面的特殊性，并通过系统建模、真实世界研究以及建立体现中医药特点的中医生命质量评价量
表，全面、综合地反映中成药防治重大慢性病的经济学价值，从而更好地体现中成药防治重大慢性病的优势。
关键词 中成药；重大慢性病；药物经济学；慢性病防治；评价体系

Construction of the pharmacoeconomic evaluation system of Chinese patent medicine in the prevention
and treatment of major chronic diseases
3
1
4
1
2
XU Gan ，LUO Weihua ，WANG Yuwei ，GUO Dongmei ，YE Hua ，SUN Yu ，ZHUANG Wei ，ZHU Wentao 1
1
1
（1. School of Management，Beijing University of Chinese Medicine，Beijing 102488，China；2. School of
Pharmacy，Fudan University，Shanghai 201203，China；3. Center for Drug Evaluation of the National Medical
Products Administration，Beijing 100022，China；4. Dept. of Pharmacy，Xuanwu Hospital，Capital Medical
University，Beijing 100053，China）
ABSTRACT OBJECTIVE To explore the construction of system of pharmacoeconomic evaluation for Chinese patent medicine in
preventing and treating major chronic diseases. METHODS The problems in pharmacoeconomic evaluation of Chinese patent
medicine for preventing and treating major chronic diseases were analyzed. Based on the problem，the pharmacoeconomic theory，
tools and methods that can be used to systematically evaluate the prevention and treatment of major chronic diseases by Chinese
patent medicine were explored to build the relevant pharmacoeconomic evaluation system. RESULTS & CONCLUSIONS
Traditional Chinese medicine shows the advantages in the prevention and treatment of major chronic diseases. This unique
advantage needed to be explored，reflected and proved in the pharmacoeconomic evaluation. The pharmacoeconomic evaluation of
Chinese patent medicine had made some progress in recent years. However，there were still deficiencies of theory and methodology
in the pharmacoeconomic evaluation for the advantages of Chinese patent medicine in preventing and treating major chronic
diseases. It was difficult to truly and comprehensively reflect the value of Chinese patent medicine by simply applying the economic
evaluation indicators and technologies of chemical medicine. It is necessary to focus on the unique pharmacoeconomic attributes of
Chinese patent medicine，excavate the economic value indicators of Chinese patent medicine for“preventive treatment of disease”
and playing the self-regulation role of human body，comprehensively consider the pharmacoeconomic particularity of Chinese patent
medicine in respects of research design，research angle，target population，intervention measures and control selection，research
time limit and evaluation method，etc. Through the use of system modeling，real-world research and the establishment of Chinese
medicinal quality of life scale that reflects the characteristics of TCM，the economic value of Chinese patent medicine in the
prevention and treatment of major chronic diseases is reflected
Δ 基金项目 中国药品监管科学行动计划第二批重点项目（No.国
comprehensively，so as to reflect the advantage of Chinese
药监科外〔2021〕37 号）；北京中医药大学基本科研业务费项目（No.
patent medicine in preventing and treating major chronic
2021-JYB-XJSJJ-037）
＊第一作者 副主任药师，博士。研究方向：药事管理、药品监管科 diseases.
学。E-mail：xgcg@163.com KEYWORDS Chinese patent medicine； major chronic
# 通信作者 教授，博士生导师，博士。研究方向：中药药物经济学 diseases； pharmacoeconomics； prevention and treatment of
评价。E-mail：wentao67@126.com chronic diseases；evaluation system

·2060 · China Pharmacy 2022 Vol. 33 No. 17 中国药房 2022年第33卷第17期